Fox Run Management L.L.C. Acquires New Shares in Vir Biotechnology, Inc. (NASDAQ:VIR)

Fox Run Management L.L.C. bought a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 49,651 shares of the company's stock, valued at approximately $364,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VIR. State of Alaska Department of Revenue lifted its holdings in shares of Vir Biotechnology by 33.0% during the fourth quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company's stock worth $1,485,000 after buying an additional 50,199 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company's stock valued at $8,496,000 after purchasing an additional 136,087 shares during the last quarter. State Street Corp boosted its holdings in Vir Biotechnology by 10.4% in the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company's stock valued at $42,135,000 after purchasing an additional 530,645 shares during the period. Rhumbline Advisers grew its position in Vir Biotechnology by 0.5% in the 4th quarter. Rhumbline Advisers now owns 236,681 shares of the company's stock worth $1,737,000 after purchasing an additional 1,288 shares during the last quarter. Finally, abrdn plc bought a new position in shares of Vir Biotechnology during the 4th quarter worth about $2,666,000. Institutional investors and hedge funds own 65.32% of the company's stock.

Insiders Place Their Bets

In other Vir Biotechnology news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. This trade represents a 8.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 10,960 shares of the business's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares of the company's stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,859 shares of company stock valued at $326,458 in the last 90 days. 15.60% of the stock is currently owned by insiders.

Remove Ads

Vir Biotechnology Price Performance

Shares of VIR traded up $0.03 on Friday, hitting $6.70. The company's stock had a trading volume of 717,714 shares, compared to its average volume of 1,310,219. The company has a market capitalization of $918.86 million, a PE ratio of -1.71 and a beta of 1.17. Vir Biotechnology, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $14.45. The company has a 50 day moving average price of $8.80 and a 200 day moving average price of $8.36.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $12.37 million for the quarter, compared to analysts' expectations of $8.14 million. On average, equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

VIR has been the subject of several research reports. Morgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. JPMorgan Chase & Co. lifted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. Leerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Finally, Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).